<DOC>
	<DOC>NCT01523418</DOC>
	<brief_summary>The primary objective of this study is to evaluate the safety of Xarelto in the prophylaxis of VTE in Indian patients undergoing elective TKR/THR</brief_summary>
	<brief_title>Study to Observe Safety of Xarelto in VTE Prophlylaxis After Elective TKR (Total Knee Replacement) or THR (Total Hip Replacement)</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Adult patients of either sex, undergoing elective THR/TKR, in whom, Rivaroxaban is given for thromboprophylaxis Patients willing to give a written informed consent Exclusion criteria must be read in conjunction with the local product information Patients on UFH / LMWH therapy, fondaparinux and vitamin K antagonists are not eligible. Patients with history of hypersensitivity to active ingredients or excipient :cellulose microcrystalline, croscarmellose sodium, lactose monohydrate, magnesium stearate, sodium lauryl sulfate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Xarelto</keyword>
	<keyword>Thromboembolism, Venous</keyword>
	<keyword>Orthopedic surgery</keyword>
	<keyword>Factor Xa inhibitor</keyword>
	<keyword>Observational study</keyword>
</DOC>